Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotech – A look back at 2024 with CEO

By HC Andersen Capital
ExpreS2ion Biotech Holding

Together with ExpreS2ion Biotechnologies' CEO, Bent Frandsen, we looked back at the main achievements in 2024, which was the first year of implementing the new strategy. The company has focused on leveraging the platform to advance assets with shorter development timelines, and it has also been a year with good progress in the pipeline. 

In the interview, you can hear more about the progress of the breast cancer candidate, external validation through partnerships, and lastly which milestones investors should look out for in 2025.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 11:27, 18 December 2024.

Recent videos

GomSpace - Strategic direction & Q&A
2026-01-19 14:00 GomSpace Group
Oncopeptides, Audiocast, Investor Conference, 2026
2026-01-16 09:00 Oncopeptides
Duell, Webcast, Q1'26
2026-01-14 09:30 Duell
Dustin Group, Audiocast, Q1'26
2026-01-14 09:00 Dustin Group
Herantis Pharma Plc, Phase 1b biomarker data webcast
2026-01-08 11:00 Herantis Pharma
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.